CSL overview
Stories about CSL
Cerberus, Ampersand agree $3.1bn biotech exit
The private equity firms have agreed to sell Talecris Biotherapeutics, purchased for $590m in 2005, to Australian blood products company CSL.
CSL contact information
Offices
655 Elizabeth Street, , Melbourne, 3000, AustraliaContacts
| Name | Job title | Location | |
|---|---|---|---|
 Ms. Joy Linton | Job titleChief Financial Officer | LocationMelbourne, Australia | Email  ----- |
| Mr. Paul McKenzie | Job titleChief Executive Officer & Managing Director | LocationMelbourne, Australia | Email -------- |
CSL fund commitments
Known fund commitments: 2
| Fund | Manager | Commitment date | Commitment size |
|---|---|---|---|
Manager ----------- | Commitment date- | Commitment size- | |
Manager ----- | Commitment dateApr 2026 | Commitment size ----- | |
Stories that mention CSL
Cerberus-backed biotech firm files $894m IPO
This is the firm's third exit attempt for Talecris, which previously had a $3bn trade sale and $1bn IPO fall apart. If successful, it would be the largest US IPO in 2009.